DECIDE Registry

Empowered decision making.

- The **largest prospective registry** of its kind with multi-site, real-world insights to set a new standard of cardiovascular care
- Building upon clinical data supporting the use of HeartFlow Plaque Analysis insights to empower clinical decision making for patients with suspected coronary artery disease[1]

Study Goal	Understand changes in medical management with insights from HeartFlow Plaque Analysis, the only FDA cleared AI-enabled plaque quantification tool validated in a prospective international trial against the gold standard of invasive imaging[2]
Endpoints	**Primary:** Change in medical management following HeartFlow Plaque Analysis compared to following CCTA alone **Secondary:** Observed outcomes and biomarkers **Safety:** MACE - death, MI, and urgent hospitalization leading to revascularization
Population	Real-world evidence from around 25 U.S. sites and patients with aim to include 10,000 patients
Study Design	HeartFlow Plaque Analysis will be provided for patients who underwent CCTA 90 days prior to the start of the registry. Armed with the addition of quantified and characterized plaque insights, treating physician will determine changes to medical management. In addition, Plaque Analysis will be used prospectively and will have arms for CCTA only and stress test only



The DECIDE Registry underscores the rigor of HeartFlow's clinical research portfolio, with evidence-directed design to offer meaningful insights.

References:

1. Rinehart et al. *JSCAI* 2024.
2. REVEALPLAQUE Study, presented at SCCT 2023.

331 E Evelyn Ave, Mountain View, CA 94041
ph: +1.650.241.1221 | info@heartflow.com | heartflow.com

HeartFlow®